Research Topics
| John ZajeckaSummaryAffiliation: Rush University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trialPhilip T Ninan
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
J Clin Psychiatry 67:15-22. 2006..To evaluate the efficacy and safety of high-dose sertraline for patients with obsessive-compulsive disorder (OCD) who failed to respond to standard sertraline acute treatment...- Augmentation strategies to increase antidepressant tolerabilityJohn M Zajecka
Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Psychiatry 68:23-7. 2007..Pharmacologic and nonpharmacologic strategies can be used to improve the tolerability of antidepressants, resulting in a greater probability of achieving and sustaining remission... - A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorderJohn M Zajecka
Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612 3824, USA
J Clin Psychiatry 63:1148-55. 2002..This study compared the efficacy, safety, and tolerability of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder... - SNRIs in the management of acute major depressive disorderJohn M Zajecka
Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Psychiatry 65:11-8. 2004..Given the available evidence and the importance of remission, the pendulum has swung to consider using agents with dual reuptake inhibition (e.g., SNRIs) as standard and initial treatment for depression... 
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled studyP E Keck
Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, and Linder Center of HOPE, Mason, Ohio 45267, USA
J Affect Disord 112:36-49. 2009..To evaluate the efficacy and safety of aripiprazole as acute and maintenance of effect monotherapy for acute bipolar mania...- Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trialA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:347-54. 2005..Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy... - Antidepressant dosing and switching guidelines: focus on nefazodoneJohn Zajecka
Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
J Clin Psychiatry 63:42-7. 2002..In clinical trials, the efficacy of nefazodone was most clearly established at doses between 300 and 600 mg/day. At this dose range, discontinuations because of adverse events are low... - Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trialJohn Zajecka
Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Psychopharmacol 30:135-44. 2010..The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder... - Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
J Clin Psychiatry 68:1014-23. 2007..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression... - Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg
Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
Biol Psychiatry 54:806-17. 2003..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD... - Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
J Clin Psychiatry 63:434-41. 2002..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction... - Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment... - Treating depression to remissionJohn M Zajecka
Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Psychiatry 64:7-12. 2003.... - A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorderRichard C Shelton
Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn, USA
J Clin Psychiatry 67:1674-81. 2006..The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in outpatients with major depressive disorder... - Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorderJohn M Zajecka
Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, Ill, USA
CNS Spectr 11:1-11; discussion 12-3; quiz 14-6. 2006..The aim is to educate clinicians about ways to diagnose and treat the mood state aggressively and safely, especially in light of the many new treatment options available... - Preventing recurrent depression: long-term treatment for major depressive disorderPierre Blier
Department of Psychiatry, Institute of Mental Health Research, University of Ottawa, Canada
J Clin Psychiatry 68:e06. 2007..Maintenance therapy considerations for clinicians include assessing treatment guidelines, addressing nonadherent patients, and measuring medication treatment response... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller
Brown University, Providence, Rhode Island 02906, USA
Biol Psychiatry 62:1371-9. 2007..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller
Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
J Clin Psychiatry 68:1246-56. 2007..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression... - Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomesDennis A Revicki
Center for Outcomes Research, MEDTAP International, Bethesda, MD 20814, USA
J Clin Psychiatry 64:288-94. 2003..This study compares the clinical, health-related quality of life (HRQL), and economic outcomes of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder... - Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 casesJohn M Zajecka
J Clin Psychiatry 69:1016-8. 2008
Research Grants
- Prevention of Recurrence in Depression with Drugs and Cognitive TherapyJohn Zajecka; Fiscal Year: 2007....
- Prevention of Recurrence in Depression with Drugs and Cognitive TherapyJohn Zajecka; Fiscal Year: 2009....
- 2/2-Prevention of Relapse & Recurrence of Bipolar DepressionJohn Zajecka; Fiscal Year: 2009..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
- Prevention of Recurrence in Depression with Drugs and Cognitive TherapyJohn M Zajecka; Fiscal Year: 2010....
- 2/2-Prevention of Relapse & Recurrence of Bipolar DepressionJohn M Zajecka; Fiscal Year: 2010..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..